| 产品描述: | Itacitinib (INCB39110)是Janus-associated kinase 1 (JAK1)的抑制剂,具有口服生物活性和潜在的抗肿瘤活性 |
| 靶点: |
JAK1;JAK |
| 体外研究: |
INCB039110是有效的、选择性的JAK1抑制剂,对JAK1的选择性分别是对JAK2和JAK3的20和200倍以上。对JAK1、2、3和TYK2的活性分别为2, 63, >2000 和 795 nM |
| 体内研究: |
使用临床剂量的INCB039110,无论是其单药给药还是和毒性药剂如gemcitabine组合给药,可在携有胰腺异种移植瘤的小鼠中阻止肿瘤的生长 |
| 细胞实验: |
Cell lines: Monocyte-Derived Macrophages Concentrations: 1 μM Incubation Time: 1 h Method: Cells were treated with various concentrations of Itacitinib. |
| 动物实验: |
Animal Models: Male Sprague-Dawley rats Dosages: 30 mg/kg Administration: s.c. |
| 参考文献: |
1. Kettle JG, et al. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1. Expert Opin Ther Pat. 2017, 27(2):127-143 2. Jun Li, et al. Abstract 779: Blockade of the IL-6/JAK/STAT3 signaling pathway inhibits pancreatic tumor cell growth in 3D spheroid cultures and in xenograft models . AACR; Cancer Res. 2015, 75(15 Suppl):Abstract nr 779. 3. Lescoat A, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol. 2020 Aug;178:114103. 4. Chen Y, et al. Zhuye Shigao Decoction Combined with Qingqi Huatan Pills in Alleviating the Acute Exacerbation of Chronic Obstructive Pulmonary Disease (Phlegm-Heat Stagnating in the Lungs) via the IL-6-Mediated JAK1/STAT3 Signaling Pathway. Evid Based Complement Alternat Med. 2022 May 6;2022:7942623. |
| 溶解性: |
Soluble in DMSO、Ethanol |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.807 ml |
9.033 ml |
18.066 ml |
| 5 mM |
0.361 ml |
1.807 ml |
3.613 ml |
| 10 mM |
0.181 ml |
0.903 ml |
1.807 ml |
| 50 mM |
0.036 ml |
0.181 ml |
0.361 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |